Recent Company News

• 04:25 AM ET Feb 11, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 01:15 AM ET Apr 30, 2026
  

  Addex Therapeutics reports Q4 net loss (CHF6.7M) vs year-ago CHF7.1M (CHF 0.05, 0.00)

• 01:20 AM ET Apr 23, 2026
  

  Addex spin-out company Neurosterix on track to complete Phase 1 clinical study of NTX-253 for schizophrenia in Q2 2026 (CHF 0.05, 0.00)

• 01:03 AM ET Apr 21, 2026
  

  Addex GABAB PAM candidate demonstrates robust anti-tussive activity in non-human primate chronic cough model (CHF 0.04, 0.00)

• 01:13 AM ET Feb 03, 2026
  

  Addex Therapeutics announces publication of data in Molecular Psychiatry demonstrating that targeting mGlu7 with negative allosteric modulators could be transformative in treatment of anxiety and fear-related disorders (CHF 0.05, 0.00)